https://www.selleckchem.com/products/byl719.html
To evaluate efficacy, pharmacokinetics (PK) and pharmacodynamics of single-agent everolimus in pediatric patients with radiographically progressive low-grade glioma (LGG). Everolimus was administered at 5mg/m once daily as a tablet or liquid for a planned 48-week duration or until unacceptable toxicity or disease progression. Patients with neurofibromatosis type 1 were excluded. PK and pharmacodynamic endpoints were assessed in consenting patients. Twenty-three eligible patients (median age 9.2years) were enrolled. All patients received
Aimer
Commentaire
Partagez
